Lupin Share Price in Focus; Company Launches Biosimilar Ranibizumab Across Europe

Lupin has taken its biosimilar eye treatment to the European market. Its commercial partner, Sandoz, has launched Ranluspec across Europe, except Germany, following approval from the European Commission. 

The drug is a biosimilar version of Ranibizumab and has been approved in both vial and pre-filled syringe forms. It is used to treat several eye conditions that can affect vision, including wet age-related macular degeneration and diabetic macular edema. 

Which Eye Conditions Does Ranluspec Treat? 

Ranluspec is used for patients with retinal diseases, including wet age-related macular degeneration, macular edema following retinal vein occlusion and diabetic macular edema. 

It is also indicated for proliferative diabetic retinopathy and choroidal neovascularisation. 

Ranibizumab works by blocking vascular endothelial growth factor A (VEGF-A), a protein involved in the growth of abnormal blood vessels in the eye. 

Lupin's Partnership with Sandoz 

Lupin said the European launch is part of its effort to make biosimilar medicines available to more patients. Thierry Volle, President of EMEA and Emerging Markets at Lupin, said the company would work with Sandoz to expand access to the treatment across the region. 

Dr Cyrus Karkaria, President of Lupin's Biotech Business, said the launch also reflects the company's work in biologics, including research and manufacturing. 

Read More: Zee Entertainment Share Price Rise 5%; Board to Consider Buyback and Interim Dividend on November 12, 2026! 

Lupin Share Price Performance 

As of November 12, 2026, at 2:47 PM, Lupin share price was trading at ₹2,015.30 per share, reflecting a 0.4% decline from previous closing price. 

Conclusion 

The European launch gives Lupin access to another market for its biosimilar Ranibizumab. The medicine will be sold through Sandoz across Europe, with Germany excluded from the launch. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.